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The human androgen receptor (AR) gene promoter lies in a GC-rich
region containing two principal sites of transcription initiation and a
putative Sp1 protein-binding site, without typical “TATA” and “CAAT”
boxes. It has been suggested that mutations within the 5’untranslated
region (5’UTR) may contribute to the development of prostate cancer
by changing the rates of gene transcription and/or translation. In order
to investigate this question, the aim of the present study was to search
for the presence of mutations or polymorphisms at the AR-5’UTR in
92 prostate cancer patients, where histological diagnosis of adenocar-
cinoma was established in specimens obtained from transurethral
resection or after prostatectomy. The AR-5’UTR was amplified by
PCR from genomic DNA samples of the patients and of 100 healthy
male blood donors, included as controls. Conformation-sensitive gel
electrophoresis was used for DNA sequence alteration screening.
Only one band shift was detected in one individual from the blood
donor group. Sequencing revealed a new single nucleotide deletion
(T) in the most conserved portion of the promoter region at position
+36 downstream from the transcription initiation site I. Although the
effect of this specific mutation remains unknown, its rarity reveals the
high degree of sequence conservation of the human androgen pro-
moter region. Moreover, the absence of detectable variation within the
critical 5’UTR in prostate cancer patients indicates a low probability
of its involvement in prostate cancer etiology.
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Introduction
Androgens play an essential role in pros-
tate differentiation and in the development
and growth of prostate carcinomas (1). The
androgen receptor protein is essential for
androgen action since it binds either testos-
terone or its 5α-reduced metabolite, 5α-di-
hydrotestosterone (2). The human androgen
receptor (AR) gene is located in the X chro-
mosome at position Xq11-12, comprising 8
exons and a long 5’untranslated region
(5’UTR). The promoter region lacks typical
“TATA” and “CAAT” boxes, but lies in a
GC-rich region and contains a putative Sp1
protein-binding site (Sp1-PBS) and two prin-
cipal transcription initiation sites (TIS) (3) as
highly conserved elements.
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The androgen receptor facilitates andro-
gen-induced regulation of genes involved in
cell proliferation and differentiation. Muta-
tions that alter AR conformation, function
and regulation may provide a selective growth
advantage for subpopulations of cells within
the tumor that are able to proliferate even in
an androgen-deprived environment (4). Since
the 5’UTR may play a role in translation
control, protein expression may also be
modulated by single-nucleotide polymor-
phisms (SNPs) in the AR promoter region, as
proposed for other prostate cancer-related
genes such as CYP17 and PSA (5,6). So far,
no SNPs have been reported in the AR-5’UTR
(http://snp.cshl.org, 7) but Crocitto and col-
laborators (8) described two germ-line point
mutations in the most conserved portion of
the promoter region among 38 individuals
with prostate cancer.
In the present study, the conformation-
sensitive gel electrophoresis (CSGE) method
was applied to the screening of the Sp1-PBS-
and TIS-containing portion (~0.5 kb) of the
androgen receptor promoter region in a
sample of prostate cancer patients in order to
determine the occurrence of germ-line muta-
tions or SNPs that could possibly affect gene
transcription or translation rates. The CSGE
method is considered to be more sensitive
than single-strand conformation polymor-
phism since the conformation polymorphism
in the DNA heteroduplexes is enhanced by
the denaturing environment, allowing the
detection of variations as small as SNPs (9).
Since human males are hemizygous for the
AR gene, we adapted the CSGE method by
the addition of corresponding polymerase
chain reaction (PCR) products from previ-
ously sequenced control DNAs. Furthermore,
CSGE was used for the analysis of a larger
AR-5’UTR (~1.3 kb) in blood donors from a
Brazilian population in order to assess its
variability.
Material and Methods
Blood samples were obtained from 100
healthy male blood donors at Hemocentro,
State University of Campinas, Campinas,
SP, Brazil. The ages of these individuals
ranged from 18 to 58 years (mean ± SD: 36.6
± 9.7 years). Genomic DNA samples from
92 prostate cancer patients were obtained
from the Urology Outpatient Clinic of the
School of Medicine of São José do Rio
Preto, SP, Brazil. The diagnosis of adenocar-
cinoma of the prostate was established by
one of the authors (J.C. Mesquita) by histo-
logical examination of specimens obtained
from transurethral resection of the prostate
or after prostatectomy. The ages of these
patients ranged from 43 to 96 years (mean ±
SD: 73.6 ± 9.2 years). The same patients
have been previously evaluated concerning
the CAG repeats and StuI polymorphism of
the AR gene and 5’promoter region polymor-
phism of the CYP17 gene (10,11).
Table 1. Primer sequences used to amplify the androgen receptor 5’UTR promoter region in blood donors and prostate cancer patients.
Primers Sequence (5'→3 ' ) Position (*) Fragment size (bp) Annealing temperature References
1S GTGAGTGCTGGCCTCCAGGA -294 to -272 425 64ºC Present paper
2AS GAGGTCACGACATGTCCTCGGC +109 to +131
3S GTTGCATTTGCTCTCCACCTCCC -23 to -1 263 60ºC Present paper
4AS TCACCGAAGAGGAAAGGGCAGCTC +216 to +240
5’UTR2-S CTTCGAAGCCGCCGCCCGG +197 to +215 350 62ºC Crocitto et al. (8)
5’UTR-AS TTCTTCCGAGAATCCTCGGT +526 to +546
7S TGCAGAGAGGTAACTCCCTTTG +472 to +494 490 64ºC Present paper
8AS CGCTCTGAGAGCCTCAAAGTC +941 to +962
AS = antisense; S = sense; 5’UTR = 5’untranslated region. *Numbering according to Tilley et al. (3).
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The protocol was approved by the Ethics
Committee of the School of Medical Sci-
ences, UNICAMP. All blood samples were
collected only after informed written con-
sent was given. Information on ancestors of
the study subjects was also obtained in order
to characterize the ethnic background of both
groups. Blood donors and patients were clas-
sified as “white” (Caucasian origin) and “non-
white” (African descent). Among blood do-
nors, 72% considered themselves white and
28% reported African ancestry. Ninety-one
percent of the patients (N = 84) considered
themselves white and only 9% (N = 8) had
parents or grandparents of African ancestry.
None of the individuals reported Amerin-
dian or Asian ancestry in the two previous
generations.
Genomic DNA for the PCR was isolated
from blood leukocytes by standard methods
(12). Four different primer sets were used to
cover about 1.3 kb of the promoter region
(Table 1) for DNA screening in the healthy
individuals. Only the most conserved por-
tion encompassing the Sp1-PBS and the two
transcription initiation sites was analyzed in
prostate cancer patients by amplification with
two pairs of primers (1S/2AS and 3S/4AS)
in separate reactions. PCR amplifications
were performed in 50-µl reaction mixtures
containing 200-500 ng genomic DNA, 0.2
mM dNTPs, 1.5 mM MgCl2, 20 pmol of each
primer, 1X PCR buffer and 1 U Taq DNA
polymerase (Gibco-BRL, Gaithersburg, MD,
USA). After a first denaturation step (5 min
at 94ºC), samples were subjected to 35 cycles
of amplification at 94ºC for 90 s, annealing
at 60-64ºC for 90 s and extension at 72ºC for
90 s, followed by a final extension step at
72ºC for 5 min. After amplification, PCR
products were analyzed in ethidium bro-
mide-stained agarose gels to confirm the
predicted size of the fragments.
CSGE was performed on 10% acrylam-
ide gel with 1.4-Bis (acryl oil) piperazine,
15% formamide and 10% ethylene glycol
(13). Samples were prepared by mixing 5 µl
of the PCR product from a previously se-
quenced control DNA with 5 µl of the PCR
product of each corresponding fragment, and
then incubated at 98ºC for 5 min, followed
by 60-90 min at 68ºC. After this step, 5 µl of
loading buffer (20% ethylene glycol, v/v,
and 30% formamide, v/v, containing 0.025%
xylene cyanol and 0.025% bromophenol
blue) was added to each sample, which was
then applied to the gel.
The CSGE was run at 300 V for 16 h at
room temperature and stained with ethidium
bromide. Sequence analysis was performed
with the ThermoSequenase Radiolabeled Ter-
minator cycle sequencing kit (Amersham,
Cleveland, OH, USA) using radiolabeled 2',3'-
dideoxynucleoside-5'-triphosphate nucleotide
analogs (α-[33]-ddNTPs). Sequencing was car-
ried out twice with products from different
PCR assays and with both sense and antisense
primers to confirm the result.
Results and Discussion
CSGE band shift was evident in only one
sample from an individual in the blood do-
nor group, with the product of primers 3S/
4AS. A T deletion (Figure 1) was located 24
































Figure 1. Sequencing analysis
by conformation-sensitive gel
electrophoresis of the mutation
that caused the differential mi-
gration pattern. The four lanes
on the left correspond to the
normal promoter gene se-
quence. The four lanes on the
right are from the blood donor’s
sample where the shift was de-
tected. The arrow indicates the
presence of the T base in the
normal sequence.
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nucleotides downstream from the TIS I (+36).
No band shifts were detected in the samples
from the prostate cancer patient samples.
The AR gene belongs to the nuclear re-
ceptor super-family and its functional do-
mains have been well established and char-
acterized. Several trinucleotide repeat se-
quences are found in the first exon of this
gene, coding for the NH2-terminal region
required for transcriptional activation (14).
One of them is a polymorphic glutamine
repetition beginning at codon 58 in humans,
and its expansion is associated with Ken-
nedy’s disease (15,16) while shorter CAG
repeat lengths were found to correlate with
an increased risk of aggressive prostate can-
cer (17).
Most of the molecular alterations detected
in patients with prostate cancer are somatic
mutations in coding regions, being distrib-
uted all over the AR gene (18). Of a total of
61 AR molecular alterations found in pros-
tatic cancer tissue, only 4 are germ-line mu-
tations (18). One of them, a germ-line muta-
tion at codon 726 in exon 5 (R726L), was
detected in two apparently unrelated Finnish
prostate cancer patients (19). Another germ-
line mutation is the glutamine to glutamic
acid substitution at position 798 (Q798E)
that occurs in exon 6 (20), which has also
been described in two patients with partial
androgen insensitivity syndrome (21,22) and
in two individuals with azoospermia (23,24).
The other two germ-line mutations, char-
acterized by Crocitto et al. (8), were located
in the TIS II (G2T) and within one of the GC-
rich regions of the 5’UTR (C214A). Accord-
ing to these investigators, these molecular
alterations may contribute to the etiology of
prostate cancer, changing the rates of gene
transcription and/or translation.
In the present study, only one new muta-
tion was detected, a T deletion at position
+36, downstream from the TIS I (Figure 2).
This mutation is located between the TIS
and a GC-rich sequence within the same
region where the two previously reported
germ-line 5’UTR mutations were found (8).
The deletion was detected in one healthy
blood donor, a 45-year-old individual of
Caucasian descent and father of three chil-
dren. In this case, only in vitro expression
and/or follow-up studies may permit us to
determine whether this deletion compromises
the AR gene function.
Considering that many genes are involved
in prostate cancer etiology, we did not ex-
pect to find a large number of DNA se-
quence alterations in the AR promoter region

























Figure 2. Schematic representa-
tion of the androgen receptor
promoter region according to
Tilley et al. (3). Asterisks indi-
cate the mutation points de-
scribed by Crocitto et al. (8). The
vertical arrow shows the posi-
tion of the T deletion detected in
the present study. The lengths
of PCR products (bp) are shown
between arrows. Ap1 = Ap1 pro-
tein-binding site; AS = anti-
sense; CRE-cAMP = cAMP-re-
sponsive element; S = sense;
Sp1 = Sp1 protein-binding site;
TIS = transcription initiation site;
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fact that neither mutations nor SNPs were
detected in these patient samples suggests
that this sequence is strongly preserved to-
wards a normal male phenotype (i.e., with-
out androgen insensitivity) and that findings
such as reported by Crocitto et al. (8) would
be extremely rare. The possibility that some
molecular alterations may be missing be-
cause CSGE may be not fully accurate in
every situation needs to be taken into ac-
count. However, its sensitivity has been
shown to reach 100% when an appropriate
system of mildly denaturing solvents and
moderate denaturation temperatures is em-
ployed (13,25) as has been done in the pres-
ent study.
Sequence conservation in promoter re-
gions is usually interpreted to be an indicator
of functional importance (26). Up to now the
promoter region of the AR gene was charac-
terized only in humans (X78592, L14435),
pigs (AF331845), mice (X59591), and rats
(L15617) (27), proving to be conservative at
the Sp1-PBS protein-binding site and in the
TIS regions. These transcription-regulating
elements are located from base -50 to +50 of
the human HSARP sequence (numbering
according to Tilley et al., 3), showing iden-
tity scores of 86, 88 and 94% when com-
pared with mouse, rat and pig sequences
(28), respectively.
In the present study, the finding of only
one molecular alteration within the critical
5’UTR of the AR gene among 192 individu-
als reinforces the expected sequence conser-
vation of this promoter region by vital selec-
tive pressure. Moreover, the absence of de-
tectable variation in prostate cancer patients
indicates a low probability of its involve-
ment in prostate cancer etiology.
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